“…These skeletons include 14 monocyclics (cyclohexene/ ane, e.g., iso-A82775C 40 ), 62 bicyclics {benzofuran (6/5, e.g., truncateols D−L 43 ), chromen (6/6, e.g., oxirapentyns F−J 31 ), naphthalene (6/6, biscognin B 44 ), and spiro[cyclohexene/anecyclopropane] (6/3, pestalotriols A and B 45 )}, 18 tricyclics {furo[2,3-g/h]chromene (5/6/6, e.g. pestalotheols A, B, and D 46 ), pyrano[2,3-g]chromene (6/6/6, oxirapentyn K 31 ), chromene−cyclocarbonate fused (6/6/5, biscognienyne F and felinoid A 30,44 ), cyclopropa[c]benzofuran (3/5/6, biscognienyne E 44 ), spiro[chromene-cyclopropane] (6/6/3, pestaloficiols B−E 47 ), and spiro[cyclopropane-naphthalene] (3/6/6, biscognin A 44 )}, and one tetracyclic {cyclopropa [3,4]furo[2,3h]chromene, 3/5/6/6, pestaloficiol A 47 }. In this study, four new members (1−4) with two distinct types of 6/6/6 tricyclic systems were obtained, further enriching the diversity of 6/6/6 tricyclic systems (only one reported compound, 5, oxirapentyn To investigate the structure−activity relationship (SAR) of the anti-glioma activity, four new derivatives (10−13) were semisynthesized by making simple structural modifications (oxidation or hydrolysis) of the natural product oxirapentyn B (6) or oxirapentyn A (7) isolated from A. felina SYSU-MS7908 (Scheme 1).…”